WO2000007616A3 - Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons - Google Patents

Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons Download PDF

Info

Publication number
WO2000007616A3
WO2000007616A3 PCT/FR1999/001901 FR9901901W WO0007616A3 WO 2000007616 A3 WO2000007616 A3 WO 2000007616A3 FR 9901901 W FR9901901 W FR 9901901W WO 0007616 A3 WO0007616 A3 WO 0007616A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferons
cell death
inducing cell
synergy
novel agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1999/001901
Other languages
English (en)
Other versions
WO2000007616A2 (fr
Inventor
Marcel Koken
Frederique Quignon
The Hugues De
Jean-Claude Ameisen
Bels Frederic De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Centre National de la Recherche Scientifique CNRS
Priority to JP2000563299A priority Critical patent/JP2002522395A/ja
Priority to EP99936659A priority patent/EP1100528B1/fr
Priority to DE69903559T priority patent/DE69903559T2/de
Priority to SI9930133T priority patent/SI1100528T1/xx
Priority to AU51680/99A priority patent/AU5168099A/en
Priority to US09/744,605 priority patent/US7217413B1/en
Priority to AT99936659T priority patent/ATE226087T1/de
Priority to DK99936659T priority patent/DK1100528T3/da
Publication of WO2000007616A2 publication Critical patent/WO2000007616A2/fr
Publication of WO2000007616A3 publication Critical patent/WO2000007616A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Inorganic Fibers (AREA)
  • Filters And Equalizers (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne l'utilisation de nouveaux agents inducteurs de mort cellulaire, et en particulier d'un agent permettant la surexpression de la protéine PML sur les corps nucléaires, en association avec des interférons, pour induire la mort de cellules indésirables et stimuler une réaction immunitaire.
PCT/FR1999/001901 1998-07-31 1999-07-30 Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons Ceased WO2000007616A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2000563299A JP2002522395A (ja) 1998-07-31 1999-07-30 インターフェロンとの相乗作用で細胞死を誘発する新規な薬品の使用
EP99936659A EP1100528B1 (fr) 1998-07-31 1999-07-30 Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
DE69903559T DE69903559T2 (de) 1998-07-31 1999-07-30 Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
SI9930133T SI1100528T1 (en) 1998-07-31 1999-07-30 Use of novel agents inducing cell death in synergy with interferons
AU51680/99A AU5168099A (en) 1998-07-31 1999-07-30 Use of novel agents inducing cell death in synergy with interferons
US09/744,605 US7217413B1 (en) 1998-07-31 1999-07-30 Use of novel agents inducing cell death in synergy with interferons
AT99936659T ATE226087T1 (de) 1998-07-31 1999-07-30 Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
DK99936659T DK1100528T3 (da) 1998-07-31 1999-07-30 Anvendelse af hidtil ukendte midler, der inducerer celledød i samvirke med interferoner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9809886A FR2781674B1 (fr) 1998-07-31 1998-07-31 Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
FR98/09886 1998-07-31

Publications (2)

Publication Number Publication Date
WO2000007616A2 WO2000007616A2 (fr) 2000-02-17
WO2000007616A3 true WO2000007616A3 (fr) 2000-04-20

Family

ID=9529292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1999/001901 Ceased WO2000007616A2 (fr) 1998-07-31 1999-07-30 Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons

Country Status (11)

Country Link
US (1) US7217413B1 (fr)
EP (1) EP1100528B1 (fr)
JP (3) JP2002522395A (fr)
AT (1) ATE226087T1 (fr)
AU (1) AU5168099A (fr)
DE (1) DE69903559T2 (fr)
DK (1) DK1100528T3 (fr)
ES (1) ES2181461T3 (fr)
FR (1) FR2781674B1 (fr)
PT (1) PT1100528E (fr)
WO (1) WO2000007616A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
AUPR874601A0 (en) 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
US8394422B2 (en) 2002-04-26 2013-03-12 Centre National De La Recherche Scientifique (Cnrs) Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans
JP2006503852A (ja) * 2002-09-25 2006-02-02 ユニバーシティー オブ ロチェスター 抗癌薬としてのカスパーゼインヒビター
EP1563099B1 (fr) 2002-11-07 2009-07-22 Newsouth Innovations Pty Limited Induction de la transition de permeabilite mitochondriale
JP2010222289A (ja) * 2009-03-23 2010-10-07 Tokyoto Igaku Kenkyu Kiko 細胞死を予防するための医薬剤
WO2011073739A1 (fr) * 2009-12-15 2011-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, compositions pharmaceutiques et kits pour une utilisation dans le traitement d'une leucémie/d'un lymphome à lymphocytes t chez l'adulte
WO2018134260A1 (fr) * 2017-01-18 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques permettant le traitement de patients souffrant de troubles myéloprolifératifs
JP7336359B2 (ja) * 2019-03-13 2023-08-31 株式会社明電舎 配電系統制御装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
US20020001841A1 (en) * 1998-06-26 2002-01-03 Keld Kaltoft Continuous t-cell lines
IL154589A0 (en) * 2000-08-25 2003-09-17 Aventis Pharma Inc Membrane penetrating peptides and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. J. (1996), 315(1), 21-4 CODEN: BIJOAK;ISSN: 0264-6021, 1996 *
BYRD J.C. ET AL: "Old and new therapies in chronic lymphocytic leukemia: Now is the time for a reassessment of therapeutic goals", SEMINARS IN ONCOLOGY(SEMIN. ONCOL.), 25/1 (65-74), United States, XP002104744 *
CHEMICAL ABSTRACTS, vol. 124, no. 23, 3 June 1996, Columbus, Ohio, US; abstract no. 307527, SLEE, ELIZABETH A. ET AL: "Benzyloxycarbonyl -Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32--" XP002104746 *
KONIG ANDREA_(A) ROBERTA: "Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines.", BLOOD, 1997, XP002095650 *
SOIGNET S ET AL: "Clinical and laboratory studies in leukemia of an organic arsenical, melarsoprol (Meeting abstract).", PROC ANNU MEET AM SOC CLIN ONCOL;16:A10 1997, XP002104745 *

Also Published As

Publication number Publication date
PT1100528E (pt) 2002-12-31
WO2000007616A2 (fr) 2000-02-17
FR2781674B1 (fr) 2002-06-28
JP2002522395A (ja) 2002-07-23
DE69903559T2 (de) 2003-02-27
EP1100528B1 (fr) 2002-10-16
EP1100528A2 (fr) 2001-05-23
AU5168099A (en) 2000-02-28
FR2781674A1 (fr) 2000-02-04
US7217413B1 (en) 2007-05-15
ES2181461T3 (es) 2003-02-16
ATE226087T1 (de) 2002-11-15
DE69903559D1 (de) 2002-11-21
JP2014129404A (ja) 2014-07-10
DK1100528T3 (da) 2002-11-04
JP2011190280A (ja) 2011-09-29

Similar Documents

Publication Publication Date Title
WO2000024365A8 (fr) Traitement de la peau au moyen d'adenosine ou d'un analogue d'adenosine
IL132951A0 (en) Compounds preparation and use for transferring nucleic acids into cells
WO1996003515A3 (fr) Expression en surface d'une enzyme dans la therapie genique a base de promedicaments
ZA984029B (en) Acitivity enhancement of ferulic acid with dimethyl isosorbide in cosmetic compositions.
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
WO2000007616A3 (fr) Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
EP1067130A4 (fr) Derives triazolo, et inhibiteurs de chimiokines contenant ces derives comme ingredient actif
WO2000056866A3 (fr) Acides nucleiques akt, polypeptides, et leurs utilisations
HUP9903249A3 (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
EP0656069A4 (fr) Inhibiteurs de la proliferation cellulaire, preparation et utilisation.
NZ502800A (en) The use of apoptin in determining the transforming capability of tumorigenic or tumor promoting agents
AU2002304163A1 (en) Polypeptide unstabilizing protein in cells under aerobic conditions and DNA encoding the same
WO2001004297A3 (fr) Proteines humaines a domaines hydrophobes et adn codant ces proteines
HU9903098D0 (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
IL148345A0 (en) Methods of and compositions for inhibiting the proliferation of mammalian cells
AU9286098A (en) Agent for modifying the proliferation, functional activity and death of natural and tumoral cells
GB9720038D0 (en) Control
JPS6485990A (en) Antihypertestoeronemia agent
WO1999024052A3 (fr) Utilisation de la proteine h en tant qu'agent cytostatique
Won The Military Fortress in the Age of Nurhaci: Jaifan-Fort and Sarhu-Fort
SI1100528T1 (en) Use of novel agents inducing cell death in synergy with interferons
Collins Design for use, design for the millions; proposals and options of the National Industrial Design Council 1948-1960.
Storm The contact hypothesis and factors affecting the integration of women in the Canadian military.
AU2172199A (en) Improvements in and relating to the handling, treatment and storage of waste
LT97027A (en) Use of the i-rna in the pharmaceuticals for increasing of the amount of protein encoded by said rna in patient cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 563299

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999936659

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999936659

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09744605

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 1999936659

Country of ref document: EP